Full-Time

Test Engineer

Posted on 1/27/2026

UBS

UBS

10,001+ employees

Investment bank and wealth, asset manager

No salary listed

Pune, Maharashtra, India

In Person

Category
QA & Testing (1)
Required Skills
Agile
Python
Git
JUnit
SQL
Java
Mockito
iOS/Swift
Selenium
Linux/Unix
Requirements
  • Fluency in programming languages such as Java and Python.
  • Experience in understanding and writing Data Definition Language and Data Manipulation Language statements.
  • Strong knowledge of testing frameworks and tools such as JUnit, Mockito, TestNG, Cucumber, Selenium or similar.
  • Familiarity with Trading Flow and Investment Products.
  • Good understanding of the FIX protocol and/or SWIFT standards, and Agile methodology.
  • Familiarity with tools such as NOMAD and Consul, Git, GitLab, and continuous integration/continuous deployment pipelines; experience working with UNIX and Windows.
Responsibilities
  • Work closely with developers, business analysts, and other stakeholders to understand requirements and create comprehensive test plans.
  • Produce clear and concise test reports and final exit summaries that communicate outcomes and highlight key insights and recommendations.
  • Design, develop, and execute automated test scripts to ensure the quality and functionality of electronic trading systems.
  • Continuously improve testing processes and methodologies to enhance efficiency and effectiveness.
  • Manage multiple projects simultaneously with resilience and efficiency.
  • Apply strong problem-solving skills to handle complex requirements.
Desired Qualifications
  • Certification in software testing.
  • Experience in testing electronic trading systems or financial applications.
  • Ability to take charge and work independently.
  • Strong team player with excellent communication and analytical skills for fast issue and requirement analysis

UBS Group AG is a Swiss multinational financial services firm with four divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management, and the Investment Bank. It serves private, corporate, institutional, and retail clients worldwide, offering wealth planning for high-net-worth individuals, Swiss banking services, a broad range of investment products, and advisory, underwriting, and trading in equities, fixed income, rates, and FX. It earns fees from wealth and asset management, interest income from lending, and trading income from investment banking. Its aim is to help clients manage and grow wealth while delivering diversified, revenue-generating financial services across regions and asset classes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Zurich, Switzerland

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Record Q1 2026 markets revenue of $3.2 billion, driven by 29% equities and 38% fixed‑income trading growth, boosts investment banking profitability.
  • $37.4 billion in net new wealth management assets in Q1 2026, including $5.3 billion inflows in the Americas, signals successful strategy and advisor compensation changes.
  • A US national banking licence and targeted acquisitions in the Americas position UBS to expand its wealth and banking platform while maintaining Swiss capital discipline.

What critics are saying

  • A proposed $20 billion Swiss capital buffer forces UBS to hoard capital, constraining US acquisitions and $3 billion in planned share buybacks.
  • US tax policy shifts and competition from Morgan Stanley and JPMorgan risk reversing Americas wealth inflows and eroding the advisor base below 5,722.
  • A Bitcoin price crash below $50,000 could devalue UBS’s $1.12 billion MicroStrategy stake by 40–50% and trigger regulatory scrutiny of its crypto pivot.

What makes UBS unique

  • UBS combines the world’s largest global wealth manager with a leading Swiss universal bank and focused investment bank and asset management arms.
  • Its Personal & Corporate Banking division anchors a universal bank model in Switzerland, feeding high-net-worth clients into Global Wealth Management.
  • UBS leverages a global footprint with booking centers across regions to deliver integrated wealth, banking, and capital markets services to ultra‑high‑net‑worth and institutional clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Remote Work Options

Professional Development Budget

Company News

CryptoRobotics
May 8th, 2026
UBS invests $1.5M in XRP through ETFs, marking shift in institutional crypto adoption

UBS has invested $1.5 million in XRP through the Volatility Shares XRP ETF and Grayscale XRP Trust, according to a recent SEC filing. The Swiss bank holds 197,369 shares in the ETF and 317 shares in the trust. The investment represents a strategic approach to cryptocurrency exposure through regulated products rather than direct holdings, reflecting broader institutional trends favouring compliance and risk management. This comes as XRP ETFs experience significant inflows whilst Bitcoin and Ethereum face notable outflows. UBS's move signals growing institutional confidence in XRP and regulated crypto products. The development may encourage retail investors to follow suit, particularly in emerging markets, as traditional financial institutions increasingly participate in the cryptocurrency sector through compliant investment vehicles.

Investors in Healthcare
Apr 13th, 2026
DentaCore secures $168M financing to fuel Swiss dental platform expansion

DentaCore Group, a Swiss dental platform, has secured CHF150 million (US$190 million) in financing to repay existing debt and fund future acquisitions. The package includes a term loan, revolving credit facility and incremental facility. Founded in 2021, DentaCore specialises in acquiring and consolidating dental practices, clinics and laboratories. The company has rapidly scaled to over 60 dental practices and laboratories through more than 40 acquisitions. UBS served as sole mandated lead arranger, bookrunner and agent for a CHF120 million term loan and revolving credit facility. Houlihan Lokey acted as exclusive financing adviser, whilst MLL Legal provided legal counsel. In 2025, Capital Transmission, a Swiss investment company within the BCGE Group, invested in DentaCore.

Sina Finance
Apr 13th, 2026
UBS raises stake in Luye Pharma with $5.1M purchase at $0.37 per share

UBS has increased its stake in Luye Pharma (02186) by 13.95 million shares at approximately HK$2.85 per share, for a total consideration of around HK$39.84 million, according to Hong Kong Stock Exchange filings dated 2 April. Following the transaction, UBS now holds approximately 403 million shares, representing a 10.09% stake in the company. The filing notes that 218.5 million of the reported positions relate to a securities lending agreement executed alongside a convertible bond issuance disclosed on 28 June 2023.

Legal Community
Apr 13th, 2026
Advestra with UBS on CHF 100 m credit to Gasverbund Mittelland - Legalcommunity.ch

Advestra advised UBS Switzerland as coordinator, agent, fronting bank and lender, alongside the other syndicate banks as lenders, on the CHF 100 million credit facility provided to Gasverbund Mittelland, a procurement and grid company of natural and biogas active across the Plateau and Northwestern regions in Switzerland.

Structured Retail Products
Apr 13th, 2026
MerQube secures Series C funding from 7RIDGE and Deutsche Börse to scale derivatives-linked ETF platform

MerQube, a US-based index provider specialising in rules-based and derivatives-enabled strategies, has closed a Series C funding round led by 7RIDGE and Deutsche Börse Group. Existing investors including Allianz Life Ventures, Citi, Intel Capital, J.P. Morgan, Laurion Capital Management and UBS also participated, though the funding amount was not disclosed. The company plans to use the investment to scale its technology platform and expand in derivatives-linked ETF and structured product markets. MerQube focuses on providing customised index solutions and data-driven strategies for institutional clients.

INACTIVE